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ABSTRACT
The main regulator of the human tumor suppresser
gene p21
(waf1/cip1) is the transcription factor p53, but
more recently it has been suggested to be a primary
anti-proliferative target for the nuclear receptor VDR
in the presence of its ligand 1a,25-dihydroxyvitamin
D3 (1a,25(OH)2D3). To identify VDR responding reg-
ions, we analyzed 20 overlapping regions covering
the first 7.1 kb of the p21
(waf1/cip1) promoter in MCF-7
human breast cancer cells using chromatin immuno-
precipitation assays (ChIP) with antibodies against
p53 and VDR. We confirmed two known p53 binding
regions at approximate positions  1400 and  2300
and identified a novel site at position  4500. In addi-
tion, we found three VDR-associated promoter
regions at positions  2300,  4500 and  6900, i.e.
two regions showed binding for both p53 and VDR.
In silico screening and in vitro binding assays
using recombinant and in vitro translated proteins
identified five p53 binding sites within the three
p53-positive promoter regions and also five
1a,25(OH)2D3 response elements within the three
VDR-positive regions. Reporter gene assays con-
firmedtheexpectedresponsivenessoftherespective
promoter regions to the p53 inducer 5-fluorouracil
and 1a,25(OH)2D3. Moreover, re-ChIP assays con-
firmed the functionality of the three 1a,25(OH)2D3-
reponsive promoter regions by monitoring simultan-
eousoccupancyofVDRwiththeco-activatorproteins
CBP,SRC-1andTRAP220.Takentogether,wedemon-
strated that the human p21
(waf1/cip1) gene is a primary
1a,25(OH)2D3-responding gene with at least three
VDR binding promoter regions, in two of which also
p53 co-localizes.
INTRODUCTION
The biologically most active vitamin D metabolite, 1a,25-
dihydroxyvitamin D3 (1a,25(OH)2D3), is essential for mineral
homeostasis and skeletal integrity (1), but it also has important
roles in the control of the cell growth and differentiation in
normal and malignant tissues (2). The 1a,25(OH)2D3 receptor
(VDR) is a member of the nuclear receptor superfamily and
the only nuclear protein that binds 1a,25(OH)2D3 with high-
afﬁnity (Kd ¼ 0.1 nM). One key gene for understanding the
anti-proliferative action of 1a,25(OH)2D3 is the cyclin-
dependent kinase inhibitor p21
(waf1/cip1), which has been sug-
gested ﬁrst by Jiang et al. (3) to be a 1a,25(OH)2D3 target
gene. A VDR binding site, a so-called 1a,25(OH)2D3 response
element (VDRE), was suggested to be located at position
 750 in relation to the transcriptional start site (TSS) of
the p21
(waf1/cip1)gene (4). The p21
(waf1/cip1) gene is also a
transcriptional target of the tumor suppressor protein p53,
which is a transcription factor with response elements
(REs), at positions  1400 and  2300 of the p21
(waf1/cip1)
promoter (5). The p53 protein is a master regulator of a prom-
inent transcriptional network that can control the fate of cells
in response to stress and can be induced by chemotherapeutic
agents, such as 5-ﬂuorouracil (6).
An essential prerequisite for the direct modulation of gene
expression by transcription factors, such as VDR and p53, is
the location of at least one ligand-activated VDR or phos-
phorylated p53 molecule close to the basal transcriptional
machinery of a primary responding gene. This is traditionally
achieved through the speciﬁc binding of VDR or p53 to REs
within the promoter of the respective gene (7). The DNA-
binding domain of the VDR contacts the major groove of a
double-stranded hexameric DNA sequence with the con-
sensus sequence RGKTCA (R ¼ Ao rG ,K¼ G or T). In
most cases the heterodimeric partner of VDR is the retinoid
X receptor (RXR), another nuclear receptor superfamily
member, which also contacts DNA. Therefore, simple
VDREs are often formed by a direct repeat of two hexameric
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Additionally, strong DNA-binding of VDR–RXR heterodi-
mers to two hexameric motifs arranged as a direct repeat
spaced by 4 nt (DR4-type VDRE) (9) or as an everted repeat
with nine intervening nucleotides (ER9-type VDRE) have
been described (10). In contrast, p53 binds as a tetramer to
the consensus sequence RRRCWWGYYY-N-RRRCWWGY-
YY (W ¼ Ao rT ,Y¼ C or T and N can be 0 to 13 bases)
(11,12). Although individual REs have been shown to be
able to induce transactivation on their own, the observation
of multiple VDREs in several primary VDR target genes
(13–15) and of two p53-REs within the p21
(waf1/cip1) gene
(16) suggests that carrying more than one binding site for a
given transcription factor in the promoter favors the prominent
response of the gene’s transcription to the respective regulator.
Never-the-less, the average short-term transcriptional
response of most primary VDR target genes is only 2-fold
or less (17), because most of them are in parallel also
under the control of other transcription factors, such as the
p21
(waf1/cip1) gene by p53.
Ligand-binding to the VDR causes a conformational change
within the receptor’s ligand-binding domain, which results in
the replacementofco-repressorproteinsbyco-activator (CoA)
proteins of the p160-family, such as steroid receptor co-
activator 1 (SRC-1) (18), in complex with more general
CoAs, such as CREB binding protein (CBP) (19). These
CoA complexes have histone acetyltransferase activity, that
causes chromatin relaxation (20). In a subsequent step, ligand-
activated VDR changes rapidly from interacting with the
CoAs of the p160-family to those of mediator complexes,
such as thyroid hormone receptor-associated protein 220
(TRAP220), also called Med1 (21). The mediator complex
acts as a bridge from activated VDR to the basal transcrip-
tional machinery (22). In this way ligand-activated VDR
executes two tasks, the modiﬁcation of chromatin and the
regulation of transcription.
The reported VDRE within the human p21
(waf1/cip1) pro-
moter was characterized to be very weak (23) and many
studies questioned the p21
(waf1/cip1) gene being a primary
VDR target gene (17,24,25). In order to challenge these
questions, we analyzed in this study the ﬁrst 7.1 kb of the
human p21
(waf/cip1) promoter for p53 and VDR binding
regions. Whole promoter chromatin immuno-precipitation
assays (ChIP) using antibodies against p53 and VDR con-
ﬁrmed two known p53 binding regions at positions  1400
and  2300, identiﬁed a novel site at position  4500,
found three VDR-associated regions at positions  2300,
 4500 and  6900, but could not conﬁrm VDR binding to
position  750. In silico/in vitro screening identiﬁed ﬁve
p53 binding sites within the three p53-positive promoter
regions and also ﬁve VDREs within the three VDR-positive
regions. Reporter gene assays conﬁrmed the expected res-
ponsiveness of the respective promoter regions to 5-
ﬂuorouracil and 1a,25(OH)2D3 and re-ChIP assays conﬁrmed
the functionality of the three 1a,25(OH)2D3-reponsive pro-
moter regions by monitoring simultaneous occupancy of
VDR with the CoA proteins CBP, SRC-1 and TRAP220.
These data demonstrate that the human p21
(waf1/cip1) gene is
a primary VDR target gene with at least three 1a,25(OH)2
D3-responsive promoter regions, in two of which also p53
co-localizes.
MATERIALS AND METHODS
Cell culture
MCF-7 human breast cancer cells were grown in phenol red-
free DMEM, supplemented with 5% charcoal-treated fetal
bovine serum, 2 mM L-glutamine, 0.1 mg/ml streptomycin
and 100 U/ml penicillin, in a humidiﬁed 95% air / 5% CO2
incubator. Before mRNA extraction or ChIP assay the cells
were treated at a density of 50 to 60% conﬂuency for 0 to
360 min with 300 mM 5-ﬂuorouracil [Sigma-Aldrich,
St. Louis, MO, USA, diluted in dimethyl sulfoxide (DMSO)],
10 nM 1a,25(OH)2D3 (kindly provided by Dr Lise Binderup,
LEO Pharma, Ballerup, Denmark, diluted in ethanol) or
vehicle.
RNA extraction and real-time quantitative RT–PCR
Total RNA was extracted using using the Mini RNA Isolation
II kit (Zymo Research, HiSS Diagnostics, Freiburg, Germany)
and cDNA synthesis was performed for 1 h at 37 C using 1 mg
of total RNA as a template, 100 pmol oligodT18 primer and
40 U reverse transcriptase (Fermentas, Vilnius, Lithuania).
Real-time quantitative PCR was performed in an IQ-cycler
(BioRad, Hercules, CA, USA) using the dye SybrGreen I
(Molecular Probes, Leiden, The Netherlands). Per reaction,
1 U Hot Start Taq polymerase (Fermentas) and 3 mM
MgCl2 were used and the PCR cycling conditions were: 40
cycles of 30 s at 95 C, 30 s at 60 C and 30 s at 72 C. Fold
inductions were calculated using the formula 2
 (DDCt), where
DDCt is the DCt(stimulus)-DCt(solvent),DCt is Ct(p21)-Ct(ARP0) and
Ct is the cycle at which the threshold is crossed. The gene
speciﬁc primer pairs (and product sizes) were as follows: p21
gene forward 50-GCAGACCAGCATGACAGATTT-30 and
reverse 50-GGATTAGGGCTTCCTCTTGGA-30 (70 bp) and
acidic riboprotein P0 (ARP0, also known as 36B4) control
gene forward 50-AGATGCAGCAGATCCGCAT-30 and
reverse 50-GTGGTGATACCTAAAGCCTG-30 (318 bp).
PCR product quality was monitored using post-PCR melt
curve analysis.
ChIP assays
Nuclear proteins were cross-linked to genomic DNA by add-
ing formaldehyde for 10 min directly to the medium to a ﬁnal
concentration of 1%. Cross-linking was stopped by adding
glycine to a ﬁnal concentration of 0.125 M and incubating
for 5 min at room temperature on a rocking platform. The
medium was removed and the cells were washed twice with
ice-cold phosphate-buffered saline (PBS) (140 mM NaCl,
2.7 mM KCl, 1.5 mM KH2PO4 and 8.1 mM Na2HPO4.2H2O).
The cells were collected by scraping in ice-cold PBS supple-
mented with a protease inhibitor cocktail (Roche Diagnostics,
Mannheim, Germany). After centrifugation the cell pellets
were resuspended in lysis buffer [1% SDS, 10 mM EDTA,
protease inhibitors and 50 mM Tris–HCl (pH 8.1)] and the
lysates were sonicated to result in DNA fragments of 300 to
1000 bp in length. Cellular debris was removed by centrifu-
gation and the lysates were diluted1:10 in ChIP dilution buffer
[0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM
NaCl, protease inhibitors and 16.7 mM Tris–HCl (pH 8.1)].
Non-speciﬁc background was removed by incubating the
chromatin resuspension with a salmon sperm DNA/protein
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USA) for 30 min at 4 C with agitation. The samples were
centrifuged and the recovered chromatin solutions were
incubated with 5 ml of indicated antibodies overnight at
4 C with rotation. IgG (sc-2027) and the antibodies against
p53 (sc-6243), GST (sc-138), VDR (sc-1008), CBP (sc-369),
SRC-1 (sc-7216), TRAP220 (sc-5334) and phosphorylated
RNA polymerase II (Pol II) (sc-13583) were obtained from
Santa Cruz Biotechnologies (Heidelberg, Germany). The
immuno-complexes were collected with 60 ml of protein A
agarose slurry (Upstate Biotechnology) for 2 h at 4 C with
rotation. Thebeadswerepelleted bycentrifugationfor1minat
4 C at 100 g and washed sequentially for 5 min by rotation
with 1 ml of the following buffers: low salt wash buffer [0.1%
SDS, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl and
20 mM Tris–HCl (pH 8.1)], high salt wash buffer [0.1%
SDS, 1% Triton X-100, 2 mM EDTA, 500 mM NaCl and
20 mM Tris–HCl (pH 8.1)] and LiCl wash buffer [0.25 mM
LiCl, 1% Nonidet P-40, 1% sodium deoxycholate, 1 mM
EDTA and 10 mM Tris–HCl (pH 8.1)]. Finally, the beads
were washed twice with 1 ml TE buffer [1 mM EDTA and
10 mM Tris–HCl (pH 8.0)]. For re-ChIP the immuno-
complexes were eluted by adding 100 ml re-ChIP elution
buffer (10 mM DTT) at room temperature for 30 min with
rotation, the supernatant was diluted 1:40 in ChIP dilution
buffer and the antibody against the second protein of interest
was added, the new immuno-complexes were allowed to form
by incubating at 4 C overnight on a rocking platform, the
immuno-complexes were collected by incubating with
120 ml protein A agarose slurry at 4 C for 2 h on a rocking
platform and ﬁnally washed as indicated above. In both cases
the immuno-complexes were then eluted by adding 250 ml
elution buffer (1% SDS and 100 mM NaHCO3) and incubation
for 15 min at room temperature with rotation. After centrifu-
gation, the supernatant was collected and the cross-linking was
reversed by adding NaCl to ﬁnal concentration of 200 mM and
incubating overnight at 65 C. The remaining proteins were
digested by adding proteinase K (ﬁnal concentration 40 mg/ml)
and incubation for 1 h at 45 C. The DNA was recovered by
phenol/chloroform/isoamyl alcohol (25/24/1) extractions and
precipitated with 0.1 volumes of 3 M sodium acetate (pH 5.2)
and 2 vol of ethanol using glycogen as a carrier.
PCR of chromatin templates
For each of the 20 regions of the human p21
(waf1/cip1) promoter
primer pairs were designed (Table 1), optimized and con-
trolled by running PCR with 25 ng genomic DNA (input)
as a template. When running immuno-precipitated DNA (out-
put) as a template, the following PCR proﬁle was used: pre-
incubation for 5 min at 95 C, 40 cycles of 30 s at 95 C, 30 s at
a primer-speciﬁc annealing temperature (see Table 1) and 30 s
at 72 C and one ﬁnal incubation for 10 min at 72 C. The PCR
products were separated by electrophoresis through 2.0%
agarose. An aliquot of 1 ml SybrGreen (1:2500 dilution)
was added to each PCR mix before loading.
DNA constructs
Full-length cDNAs for human VDR (26) and human RXRa
(27) were subcloned into the T7/SV40 promoter-driven pSG5
expression vector (Stratagene, LaJolla, CA, USA). The same
constructs were used for both T7 RNA polymerase-driven
in vitro transcription/translation of the respective cDNAs
and for viral promoter-driven overexpression in mammalian
cells. Promoter regions 1 (+20 to  321), 2, 3, 5, 7 (extended,
from  1954 to  2620), 12C (extended, from  3818 to
 4525) and 19 of the human p21 promoter (for location
see Table 1) were cloned by PCR from human genomic
DNA and fused with the luciferase reporter gene. (+20 to
 321) Point mutations to the promoter region 7 construct
were generated using the QuickChange site-directed mutagen-
esis kit (Stratagene) according to the manufacturer’s instruc-
tions. The location of the mutations are indicated in Figure 6B.
All constructs were veriﬁed by sequencing.
Gelshift analysis
Recombinant baculovirus expressed p53 protein (1 U/ng) was
purchased from Jena Bioscience (Jena, Germany). In vitro
translated VDR and RXR proteins were generated by coupled
in vitro transcription/translation using their respective pSG5-
based full-length cDNA expression constructs (26) and rabbit
reticulocyte lysate as recommended by the supplier (Promega,
Madison, WI, USA). Gelshift assays were performed with
100 ng recombinant p53 protein or each 10 ng of in vitro
translated VDR and RXRa protein. The proteins were incub-
ated for 15 min in total volume of 20 ml binding buffer
[150 mM KCl, 1 mM DTT, 0.2 mg/ml poly(dI-C), 5% glycerol,
10 mM HEPES (pH 7.9)]. Constant amounts (1 ng) of
32P-labeled double-stranded oligonucleotides (50000 c.p.m.)
corresponding to one copy of the putative p53-REs or VDREs
were then added and incubation was continued for 20 min at
room temperature. Core sequences of the REs are indicated in
Figure 4. An double-stranded oligonucleotide with the core
sequence GAACTCGGAAAGGCTCAGCTGGCTC served
as negative control for p53 binding, while the rat atrial
natriuretic factor (ANF) DR3-type VDRE [core sequence
AGAGGTCATGAAGGACA (28)] served as reference of
the strength of the putative VDREs. Protein–DNA complexes
were resolved by electrophoresis through 8% non-denaturing
polyacrylamide gels in 0.5· TBE buffer [45 mM Tris, 45 mM
boric acid, 1 mM EDTA (pH 8.3)] and quantiﬁed on a
FLA-3000 reader (Fuji, Tokyo, Japan) using Image Gauge
software (Fuji).
Transfection and luciferase reporter gene assays
MCF-7 cells were seeded into 6-well plates (10
5 cells/ml) and
grown overnight in phenol red-free DMEM supplemented
with 5% charcoal-stripped fetal bovine serum. Plasmid
DNA containing liposomes were formed by incubating a
reporter plasmid and the expression vector for human VDR
(each 1mg)with10 mgN-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-
trimethylammonium methylsulfate (DOTAP, Roth, Karlsruhe,
Germany) for 15 min at room temperature in a total volume of
100 ml. After dilution with 900 ml phenol red-free DMEM, the
liposomes were added to the cells. Phenol red-free DMEM
supplemented with 500 ml 15% charcoal-stripped fetal bovine
serum was added 4 h after transfection. At this time, 100 mM
5-ﬂuorouracil, 100 nM 1a,25(OH)2D3 or solvent were also
added. The cells were lysed 16 h after onset of stimulation
using the reporter gene lysis buffer (Roche Diagnostics) and
the constant light signal luciferase reporter gene assay was
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Packard, Groningen, The Netherlands). The luciferase
activities were normalized with respect to protein concentra-
tion and induction factors were calculated as the ratio of
luciferase activity of ligand-stimulated cells to that of solvent
controls.
RESULTS
Induction of p21
(waf1/cip1) mRNA expression
by 5-fluorouracil and 1a,25(OH)2D3
In MCF-7 human breast cancer cells the expression of
p21
(waf1/cip1) mRNA was monitored by real-time quantitative
RT–PCR in relation to the control gene ARP0 over a time
period of 0 to 360 min (Figure 1). Within this time the
p53 inducer 5-ﬂuorouracil provided a steady increase of
p21
(waf1/cip1) mRNA expression up to a level of 5.2-fold
after 360 min of stimulation (Figure 1A). The natural VDR
ligand 1a,25(OH)2D3 also induced p21
(waf1/cip1) mRNA
expression, but weaker and more transiently than 5-
ﬂurouracil, showing a maximum of 1.6-fold induction after
120 min of stimulation (Figure 1B). The response of the
p21
(waf1/cip1) gene to 1a,25(OH)2D3 is comparable to that of
the primary VDR target gene cyclin C [showing a maximum
1.8-foldinductionafter 2h(14)]. Moreover,bothgenes show a
high basal expression, which is  10000-fold higher than that
of the most responsive 1a,25(OH)2D3 target, the 24-hydroxy-
lase (CYP24) gene [compare ref. (14) and data not shown].
Whole p21
(waf1/cip1) promoter screening for p53 binding
In order to localize novel p53 and VDR binding sites (and to
challenge already known REs) within the human p21
(waf1/cip1)
promoter, we designed 19 overlapping primer pairs that cover
evenly the ﬁrst 7.1 kb of chromosomal DNA upstream of the
TSS (Figure 2A). To minimize the number of primers in repet-
itive sequences, we employed the web-based CENSOR server
screening service (29) to identify repetitive sequences in the
promoter sequence. We determined that the repetitive
sequence content of this segment of human chromosome
6 is 24.2%. Where possible the remaining 73.8% unique
sequence was used to design the overlapping PCR primer
pairs,butforregions 9, 10,14, 15,17 and18 oneofthe primers
Table 1. Genomic PCR primer sequences
Region no. Location in p21 promoter Annealing temperature ( C) Primer sequences
1 +37 to  342 60 50-GCTCATTCTAACAGTGCTGTG-30
50-CAAGGAACTGACTTCGGCAG-30
2  324 to  676 60 50-CCCGGAAGCATGTGACAATC-30
50-CAGCACTGTTAGAATGAGCC-30
3  677 to  981 60 50-GGAGGCAAAAGTCCTGTGTTC-30
50-GGAAGGAGGGAATTGGAGAG-30
4  964 to  1340 60 50-CTGAGCAGCCTGAGATGTCAG-30
50-CACAGGACTTTTGCCTCCTG-30
5  1335 to  1688 60 50-GAAATGCCTGAAAGCAGAGG-30
50-GCTCAGAGTCTGGAAATCTC-30
6  1670 to  2036 60 50-GGAGTCAGATTCTGTGTGTG-30
50-CCTCTGCTTTCAGGCATTTC-30
7  2029 to  2478 60 50-CACCACTGAGCCTTCCTCAC-30
50-CTGACTCCCAGCACACACTC-30
8  2456 to  2929 60 50-GTGATGCTAGGAACATGAGC-30
50-GATGTGAGGAAGGCTCAGTG-30
9  2910 to  3148 56 50-CTGAATACCTGGGACTACAG-30
50-GCTCATGTTCCTAGCATCAC-30
10  3141 to  3558 60 50-GACATAGCAGGTGTGATGACC-30
50-GTATTCAGGTGGCTGAGGTG-30
11  3538 to  3941 60 50-GAACAGGAAGACCATCCAGG-30
50-GGTCATCACACCTGCTATGTC-30
12  3940 to  4364 60 50-GATGCCAACCAGATTTGCCG-30
50-CCTGGCTCTAACAACATCCC-30
12C  4149 to  4525 60 50-CGCGGTGCTTGGTCTCTATG-30
50-CCTTTCCCAACAAACAAGGGG-30
13  4353 to  4755 60 50-CTGAAGGCAGGCAAGACTCG-30
50-CTGGTTGGCATCATCTCGCTG-30
14  4736 to  5268 60 50-GCCAGTCATGGTTGTACATGC-30
50-CGAGTCTTGCCTGCCTTCAG-30
15  5248 to  5810 60 50-CTTTGCTCCTTCTCCACTCC-30
50-GCATGTACAACCATGACTGGC-30
16  5791 to  6091 60 50-CTATGTGCCAAGCTAAGCAC-30
50-GGAGTGGAGAAGGAGCAAAG-30
17  6072 to  6333 60 50-CATCAGTTCCCGGTTCTTCTC-30
50-GTGCTTAGCTTGGCACATAG-30
18  6324 to  6731 60 50-CAAAGGCACAAAGAGGCCTTC-30
50-GGAACTGATGGAGGCTGGAG-30
19  6715 to  7083 60 50-CTAACCTCACAGTACAGGCC-30
50-GCCTCTTTGTGCCTTTGCAC-30
546 Nucleic Acids Research, 2006, Vol. 34, No. 2is located in repetitive sequence (Table 1). Moreover, due to
unspeciﬁc binding of IgG to promoter region 12 (Figure 2B),
we designed an alternative primer pair detecting region 12C
(Figure 2A).
Chromatin was extracted fromMCF-7cellsthat were grown
overnight in the presence of 5% charcoal-treated fetal bovine
serum, stimulated for 360 min with solvent (DMSO) or
300 mM 5-ﬂuorouracil and then cross-linked for 10 min in
the presence of formaldehyde. ChIP assays were performed
using an antibody against p53 and representative agarose gels
of the PCR products are shown (Figure 2B). Comparable
detection sensitivity for the 20 different p21
(waf1/cip1) promoter
regions was demonstrated by representative PCR products that
were obtained using DNA liberated from the recovered chro-
matin by reverse cross-linking (input lane). Immunoprecipita-
tions with IgG and anti-glutathione S-transferase (GST)
antibodies served as negative controls. PCR products obtained
with p53-enriched chromatinvisualized the localizationof p53
to the ﬁrst 7.1 kb of the p21
(waf1/cip1) promoter. We found
induction of p53 binding to promoter regions 1, 5, 7 and
12C. The binding to region 4 may be unspeciﬁc (see IgG
control lane), while the binding to regions 2, 6 and 13 may
represent ﬂanking effects of the ChIP method.
The relative binding of p53 to regions 1, 5, 7 and 12C was
also determined by quantitative real-time PCR (Figure 2C).
Strongest induction (70-fold) was found on the TSS (region 1),
followed by region 5(48-fold) and region 7(46-fold), while on
region 12C only a 3.7-fold induction of p53 binding could be
detected.Interestingly,regions 7and12Cshowedsigniﬁcantly
higher basal association of p53 than regions 1 and 5. For
regions 5 and 7 this conﬁrms the ﬁndings of a previous
study (30), further downstream regions of the p21
(waf1/cip1)
promoter have not been studied before. Taken together, we
could conﬁrm the expected binding of p53 to promoter regions
5 and 7and could show for the ﬁrst time binding of p53 protein
to region 12C. We presume the association of p53 with the
TSS region (region 1) is most likely a consequence of chro-
matin looping of distal regions (e.g. regions 5, 7 and 12C) to
bring them in contact with Pol II.
Whole p21
(waf1/cip1) promoter screening
for VDR binding
ChIP assays were performed using an antibody against VDR
on chromatin that was extracted from MCF-7 cells after stimu-
lation for 0, 15, 30, 60, 120 and 180 min with 10 nM
1a,25(OH)2D3. Representative agarose gels of the PCR pro-
ducts obtained with VDR-enriched chromatin visualized the
time-dependent localization of VDR to the ﬁrst 7.1 kb of the
p21
(waf1/cip1) promoter (Figure 3). We found signiﬁcant VDR
binding to promoter regions 7, 12C and 19. The VDR binding
totheTSS(region1)isagainmostlikelythesignofcomplexes
of Pol II with VDR-associated with distal promoter regions.
We consider signals at regions 2 and 13 as ﬂanking effects and
the apparent association of VDR to regions 4, 12 and 17 as
unspeciﬁc, since these two regions also bind IgG (see
Figure 2B). In summary, as an essential condition for a prim-
ary VDR target gene, the TSS of the human p21
(waf1/cip1) gene
associates with VDR. Moreover, the ﬁrst 7.1 kb of the pro-
moter contain three distal VDR binding sites in regions 7, 12C
and 19.
Identification of p53-REs and VDREs on
the human p21
(waf1/cip1) promoter
The ChIP assays with anti-p53 and anti-VDR antibodies
(Figures 2 and 3) suggest that the human p21
(waf1/cip1) pro-
moter contains multiple responsive regions for both p53 and
VDR. In order to challenge this prediction, we performed
in silico screening of the ﬁrst 7.1 kb of the p21
(waf1/cip1) pro-
moter for p53 consensus sequence RRRCWWGYYY-N-
RRRCWWGYYY and for DR3-, DR4- and ER9-type
VDREs [consensus sequence for each half-site RGKTCA
allowing one mismatch per half-site (23)]. We found ﬁve
putative p53-REs, of which three are located in promoter
region 7 and one each in regions 5 and 12 (Figure 4). More-
over, we found eight putative VDREs, of which four have a
DR3-type structure, three are DR4-type REs and one is an
ER9-typeRE.Each twooftheseVDREswere found inregions
4, 7 and 19, while each one was found in regions 3 and 12. The
DR3-type VDRE in region 3has been publishedearlier (4). No
putative RE was found in region 1.
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Figure 1. Time course of p21
(waf1/cip1) mRNA expression. Real-time quanti-
tative RT–PCR was used to determine p21
(waf1/cip1) mRNA expression relative
to the control gene ARP0 in MCF-7 human breast cancer cells in response to
300 mM 5-fluorouracil (A)o r1 0n M1 a,25(OH)2D3 (B) over a time period of
360 min. Data points indicate the means of at least three independent cell
treatments and the bars represent standard deviation. Two-tailed Student’s
t-tests were performed to determine the significance of the mRNA induction
in reference to solvent controls (*P < 0.05, **P < 0.01).
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heterodimers to putative REs
To conﬁrm further the physical association between p53 and
the identiﬁed regions gelshift experiments were performed on
double-stranded oligonucleotides containing the ﬁve putative
p53-REs sequences, using recombinant baculovirus expressed
p53 protein (Figure 5A). An oligonucleotide with mutated p53
binding sites served as negative control. Strong p53 binding
was observed to the known p53 binding site within region 7
(p53-RE2), while the p53-REs 3, 4(region 7) and 5(region12)
showed only 10–12% of this binding. The p53-RE1 (region 5)
showed only very week complex formation with p53 protein
(3%); this may reﬂect the fact that this sequence appears to
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Figure 2. Location of p53 protein within chromatin on human p21(waf1/cip1) promoter. Nineteen overlapping regions evenly cover the first 7.1 kb of the human
p21
(waf1/cip1)promoter(A)DuetoIgGbindingtoregion12analternativeregion12Cwaschosen(Table1).ChromatinwasextractedfromMCF-7cellsthathadbeen
treated for 360 min with solvent (DMSO) or 300 mM fluorouracil. ChIP assays using an antibody against p53 were performed (B) Precipitations with IgG and
anti-GST antibody served as controls for the specificity of the p53 detection. Representative agarose gels of the input lane confirm the comparable detection
sensitivity of the 20 different promoter regions. The induction of p53 binding by 5-fluorouracil to promoter regions 1, 5, 7 and 12C was determined by quantitative
real-timePCR(C)Columnsindicatethemeansofatleastthreeindependentcelltreatmentsandthebarsrepresentstandarddeviations.Aone-tailedStudent’st-tests
was performedto determinethe significanceof the increasein p53 bindingin fluorouracil-treatedsamples in referenceto solventcontrols (*P < 0.05,**P < 0.01).
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Figure 3. Ligand-modulated VDR binding to the human p21(waf1/cip1) promoter. Chromatin was extracted from MCF-7 cells that had been treated for indicated
timeperiodswith10nM1a,25(OH)2D3.ChIPassaysusinganantibodyagainstVDRwereperformed.TheVDRandRXRassociationofthe20regionsofthehuman
p21
(waf1/cip1)promoterwasmonitoredforthesixtreatmenttimes.PrecipitationswithIgGservedascontrolsforthespecificityoftheVDRdetection. Representative
agarose gels of at least three independent cell treatments are shown.
548 Nucleic Acids Research, 2006, Vol. 34, No. 2diverge signiﬁcantly from the established consensus p53 bind-
ing sequence (12). The negative control did not show any p53
binding at all.
To assess basal association between the eight putative
VDREs the gelshift assays were performed with in vitro trans-
lated VDR and RXR proteins, either alone or in combination
(Figure 4B) under conditions identical to our earlier DR3-type
VDREcomparativestudy(23).TheDR3-type VDREofthe rat
ANF gene promoter (28) served as a positive control. In ref-
erence to this control, REs 4, 5 (region 7), 6 (region 12C) and
7, 8 (region 19) showed 10–15% of VDR–RXR complex
formation. In contrast, REs 1, 2 and 3 in regions 3 and 4,
showed no binding of VDR–RXR heterodimers. Taken
together, our in silico/in vitro scanning for REs in the
human p21
(waf1/cip1) promoter provided one strong p53-RE,
four weaker p53-REs and ﬁve VDREs in regions 5, 7, 12C
and 19. In contrast, under our stringent gelshift conditions no
binding of VDR–RXR heterodimers to the described VDRE
(RE1) in region 3 could be detected.
Functionality of p53 and VDR binding site containing
regions of the p21
(waf1/cip1) promoter
PCR fragments representing regions 1, 2, 3, 5, 7, 12C and 19
of the human p21
(waf1/cip1) promoter were fused with the
thymidine kinase promoter driving the ﬁreﬂy luciferase
reporter gene. The reporter gene constructs were transfected
into MCF-7 cells, stimulated for 16 h with 100 nM
1a,25(OH)2D3 or 100 mM 5-ﬂuorouracil and relative reporter
gene activity was measured (Figure 6). Promoter regions 7,
12C and 19 showed statistically signiﬁcant induction by
1a,25(OH)2D3 (1.5- to 1.9-fold), while regions 5, 7 and
12C were also 1.5- to 1.9-fold inducible by 5-ﬂuorouracil
(Figure 6A). Regions 1, 2 and 3 were inducible by neither
of the two stimuli. Interestingly, the basal activity of the
reporter gene constructs varied signiﬁcantly with low activity
of region 19, intermediate activity of regions, 1, 2, 3 and 12C
and strong activity of regions 5 and 7 suggesting varying
amounts of other transcription factors associating with these
regions.
In order to analyze the contribution of the different REs
within promoter region 7, we introduced point mutants into the
complex VDRE 4/5 and p53-REs 2, 3 and 4 as indicated in
Figure 6B. Reporter gene assays in MCF-7 cells indicated that
all three half-sites of VDREs 4 and 5 are critical for the
responseofthepromoterregionto1a,25(OH)2D3(seemutants
1, 2 and 3 in Figure 6B) and that the p53-RE2 is essential for
the response to 5-ﬂuorouracil (mutant 4). Moreover, mutation
of the p53-RE2 reduced the basal activity by a factor of 20.
Interestingly, the mutated promoter region was still responsive
to 1a,25(OH)2D3. In contrast, mutations in p53-REs 3 and 4
did not affect the responsiveness of the promoter construct to
5-ﬂurouracil or 1a,25(OH)2D3 (mutants 5, 6 and 7).
In summary, the functional assays conﬁrmed the results
from the ChIP scanning, in silico screening and in vitro bind-
ing studies. Namely that regions 5, 7 and 12C contain func-
tional p53 binding sites and regions 7, 12C and 19 have
functional VDREs. The known p53-RE2 was conﬁrmed to
be of central importance for the basal activity of the
p21
(waf1/cip1) promoter and the complex VDRE was shown
to mediate the response of promoter region 7 to
1a,25(OH)2D3. In contrast, there is neither direct p53 nor
VDR binding in response to their inducers within the proximal
p21
(waf1/cip1) promoter (regions 1, 2 and 3).
Co-localization of VDR and its partner proteins
An additional test for the functionality of the VDREs in the
chromatin context of MCF-7 cells was performed by re-ChIP
experiments in response to 0, 15, 30, 60, 120 and 180 min
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Figure 4. In silico screening for p53-REs and VDREs in the human p21
(waf1/cip1) promoter. In silico analysis of the human p21
(waf1/cip1) promoter indicated five
putativep53-REsinpromoterregions5,7and12andeightputativeVDREs(RE1toRE8)inpromoterregions3,4,7,12and19.Thedecamericp53bindingsitesand
the hexameric nuclear receptor binding sites of each RE core sequence are shown in bold and their location relative to the TSS is indicated.
Nucleic Acids Research, 2006, Vol. 34, No. 2 549treatment with 10 nM 1a,25(OH)2D3 (Figure 7). Initial rounds
of immuno-precipitation were performed with the VDR anti-
body and then the precipitated material was interrogated fur-
ther with antibodies against CBP, SRC-1 and TRAP220. This
approach was undertaken to enrich for chromatin templates
that were associated with both VDR and its partner proteins at
the same time. Single ChIP assays with anti-phosphorylated
Pol II antibodies served as reference for the transcriptional
activity of the test promoter regions. From the double-
fractionated chromatin template, VDR was found to associate
in a 1a,25(OH)2D3-stimulated and time-dependent fashion
with CBP, SRC-1 and TRAP220 on the p21
(waf1/cip1) promoter
regions 1 (TSS), 7, 12C and 19, but not on the negative control
region 3. The association of VDR with its partner proteins
showed individual proﬁles. On regions 7 and 19 there is rather
constant association of VDR with CBP, while on region 12C
and the TSS there was a peak after 15 to 60 min of ligand
treatment. The respective VDR-CBP co-localization on the
TSS was also rather constant, but showed a maximum at
time point 15 min. Some association of VDR with SRC-1
was observed at nearly all time points with maxima at
0 and 60 min and a minimum at 120 min for region 7, a
maximum between 15 and 60 min for region 12C and maxima
for time points 0, 30 and 180 min for region 19. These rather
divergent VDR-SRC-1 association proﬁles were integrated at
the TSS with maxima at 15 and 120 min. The VDR-TRAP220
association was found to peak at 60 min for region 7, and at
60 to 180 min for regions 12C and 19. The TSS showed some
VDR-TRAP220 association already after 15 min, but the main
interaction was observed at 60 to 180 min. For regions 7 and
12C the activity of phosphorylated Pol II was highest at
60 min, while for region 19 rather constant activity was detec-
ted and even region 3 showed low level of constant association
of Pol II. The TSS integrates these activities by high basal
association with phosphorylated Pol II over all time points
with a slight maximum at 60 min.
Taken together, re-ChIP assays conﬁrmed 1a,25(OH)2D3-
dependent functionality of promoter regions 7, 12C and 19, by
p53
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Figure 5. Invitroanalysisofp53-REsandVDREswithinthehumanp21
(waf1/cip1)promoter.Gelshiftexperimentswereperformedwithrecombinantp53protein(A)
andinvitrotranslatedVDRandRXRaaloneorincombination(B)andinthepresenceof
32P-labeledREs.Anoligonucleotidewithmutatedbindingsiteswasusedas
negative control for p53 binding. Protein–DNA complexes were resolved from free probe through non-denaturing 8% polyacrylamide gels. Representative gels are
shown.Therelativeamountofp53andVDR–RXRheterodimerbindingwasquantifiedonaFLA-3000readerinrelationtheknownp53bindingsitep53-RE2andthe
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550 Nucleic Acids Research, 2006, Vol. 34, No. 2demonstrating individual association proﬁles with different
CoA proteins. Equally the data generally supported the con-
cept of initial, rapid recruitment of SRC family members
CoAs, followed subsequently by members of the mediator
complex.
DISCUSSION
In recent years 1a,25(OH)2D3 and its low-calcemic analogues
have emerged as promising anti-cancer agents. However, the
mechanisms of the anti-proliferative, pro-differentiating and
pro-apoptotic effects of VDR ligands vary and are cell-
speciﬁc. Therefore, they cannot be explained by a single
molecular pathway in all cell types, but the status of the
p53 gene, being mutated in over 50% of human tumors
(31), may be of critical impact in most cases. The p53 protein
is well known as the master regulator of the p21(waf1/cip1) gene,
which in turn for the last decade has appeared to be the most
promising 1a,25(OH)2D3 target concerning cell growth regu-
latory effects of the nuclear hormone. In this study we have
undertaken whole promoter ChIP assays covering the ﬁrst
7.1 kb of the human p21
(waf1/cip1) to characterize the critical
p53 and VDR binding sites (for summary see Table 2). For
each of the two transcription factors we found three binding
regions within the promoter. Interestingly, two of these,
regions 7 and 12C at approximate positions  2300 and
 4500 relative to the TSS, were identical for both, i.e. they
containbothp53-REs andVDREs. This leaves onlyregion5at
position  1400 unique for p53 binding and region 19 at posi-
tion  6900 restricted to VDR binding. Functional studies
conﬁrmed the responsiveness of the respective regions to
the p53 inducer 5-ﬂuorouracil and VDR activation by
1a,25(OH)2D3, respectively.
The p53 binding regions 5 and 7 have been well character-
ized by others by a range of approaches including ChIP assays
(16,30,32). However, due to the fact that most analyses of the
p21
(waf1/cip1) promoter were restricted to the ﬁrst 3 kb, the
novel p53 binding site at position  4000 (region 12) have
been overlooked so far. In vitro gelshift analysis indicated a
10-fold lower binding afﬁnity of this novel site, compared to
the perfect site at position  2300 (region 7), and quantitative
real-time PCR from released chromatin template in ChIP
assays detected 10-fold less induction of p53 binding to
that p21
(waf1/cip1) promoter region. In contrast, this novel
p53 binding region demonstrated signiﬁcant induction after
5-ﬂuorouracil treatmentinreportergene assaysandrather high
basal association with p53 in quantitative ChIP assays.
Binding of p53 to the p21
(waf1/cip1) promoter in the absence
of genotoxic signals have also been observed previously (32).
Since thep21
(waf1/cip1)promotercontainsonehigh- andseveral
low-afﬁnity sites, it may support a hypothesis that afﬁnity
dictates the choice between cell cycle arrest and apoptosis,
with high-afﬁnity sites regulating cell cycle arrest and low-
afﬁnity sites regulating pro-apoptotic effects (33). In cells with
a wild-type p53 gene the novel p53-RE at position  4000 may
be of minor impact for the response of the p21
(waf1/cip1) gene to
cellular stress mediated by p53, but still critical for the induc-
tionofapoptosis.Moreover,incasesofp53gene mutationsthe
elevated p53 protein association to region 12 and the location
ofafunctionalVDREmaybecomeofhigherimpact.Thesame
holds true for region 7, which contains a very potent p53-REs
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Figure 6. Functionality ofp21
(waf1/cip1) promoter constructs.Reportergeneassayswere performedwithextractsfrom MCF-7cells thatweretransientlytransfected
withluciferasereporterconstructscontainingregions1,2,3,7,12Cor19ofthehumanp21
(waf1/cip1)promoter(A)orwild-typeandmutatedformsofregion7(B)and
anexpressionvectorforhumanVDR.ThedinucleotidesbelowtheREsequencesindicatethepointmutationsthatwereintroducedintopromoterregion7.Cellswere
treated for 16 h with either solvent, 100 nM 1a,25(OH)2D3 or 100 mM fluorouracil. Relative luciferase activity is shown. Columns represent means of at least three
experiments and bars indicate standard deviations. Two-tailed Student’s t-tests were performed to determine the significance of the reporter gene induction in
reference to solvent controls (*P < 0.05).
Nucleic Acids Research, 2006, Vol. 34, No. 2 551and a complex VDRE. Therefore, we hypothesize that high
basal p53 binding paired with closely located VDREs may
represent a integrated system to assure sufﬁcient p21
(waf1/cip1)
mRNAexpressioneven incaseswhere regularp53signaling is
impaired by mutations.
In cells, such as the MCF-7 breast cancer cells that were
used in this study, having a wild-type p53 gene, the basal
p21
(waf1/cip1) mRNA expression appear elevated, compared
to other VDR target genes, such as CYP24. The drastic loss
of basal activity of promoter region 7 by mutagenesis of its
potent p53-RE supports this view. Moreover, possibly reﬂect-
ing this treatment with 1a,25(OH)2D3 results only in a minor
1.6-fold further elevation of mRNA levels. This may indicate
that cells with wild-type p53 gene have already sufﬁciently
high p21
(waf1/cip1) protein levels, so that they need not take
advantage of the 1a,25(OH)2D3 signaling pathway to further
increase their p21
(waf1/cip1) expression. This may also explain
the varied observations concerning the response of the
p21
(waf1/cip1) gene to 1a,25(OH)2D3, found by various groups.
The adjacent functional response elements for p53 and VDR
suggestthatthesefactorsco-operateinnormalbreastepithelial
cells, perhaps to regulate p21
(waf1/cip1) mRNA levels, such that
in 1a,25(OH)2D3-replete environments the p53 activation of
the gene is very readily undertaken to bring about cell cycle
control and/or programmed cell death. Anyway, the demon-
stration of functional 1a,25(OH)2D3-responding promoter
regions conﬁrms that the p21(waf1/cip1) is a primary
1a,25(OH)2D3-responding gene.
The CYP24 gene probably is the most responsive primary
VDR target gene, because its protein product leads to the
degradation of 1a,25(OH)2D3 and therefore the eventual
extinction of the transcriptional signal (13). Therefore, it
makes sense that VDR–RXR heterodimers are the central
transcription factors on the CYP24 promoter and that the
basal expression of the gene in the absence of an activating
signal for VDR–RXR heterodimers is very low (14). Thus the
CYP24 gene appears to be somewhat of a special example of
VDRgene regulation. Incontrast, the basal expression of other
VDRtargetgenes,suchascyclinC,PPARdandp21,is10000-
to 100000-times higher as that of the CYP24 gene (14,34)
suggesting that also other transcription factors than VDR–
RXR heterodimers contribute tothe gene’s activity. Therefore,
the stimulation of the gene’s mRNA expression is elevated
from a high level only 1.5- to 3.0-fold, which still represents
the production of more mRNA molecules than in case of a
1000-fold stimulation of the CYP24 gene. The promoters for
the genes CYP24 and cyclin C contain four VDREs (13,14)
and the insulin-like growth factor binding proteins 1, 3 and 5
genes each carry three VDREs in their promoter (15). Thus the
number of VDREs within a promoter does not correlate with
the inducibility of a VDR target gene. The p21 promoter
contains three 1a,25(OH)2D3-responsive regions (7, 12C
and 19, see also Table 2), each of which show
1a,25(OH)2D3-dependent recruitment of CoA proteins to
VDR-bound chromatin regions. Moreover, each of the three
promoter regions contains at least one VDRE. This conﬁrms
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Figure 7. VDR complexes on1a,25(OH)2D3-responsivep21
(waf1/cip1)promo-
terregions.ChromatinwasextractedfromMCF-7cellsthathadbeentreatedfor
indicated time periods with 10 nM 1a,25(OH)2D3. Re-ChIP experiments were
performed with a first immuno-precipitation with anti-VDR and a second
precipitation with anti-CBP, anti-SRC-1 and anti-TRAP220 antibodies as in-
dicated.RegularChIPassayswithanti-phosphorylatedPol IIantibodyserveas
a positive control and precipitations with IgG as specificity controls. The
associations of VDR and its partner proteins were monitored on the human
p21
(waf1/cip1) promoter regions 1 (TSS), 3 (negative control), 5, 7, 12C and 19.
Representative agarose gels are shown.
552 Nucleic Acids Research, 2006, Vol. 34, No. 2again the rule of the multiple VDREs in primary
1a,25(OH)2D3-responsive genes. Please note that the previ-
ously suggested VDRE [RE1 (4)] is not binding VDR–RXR
heterodimers and is located in the non-1a,25(OH)2D3-
responsive promoter region 3 (position  750).
In conclusion, our study provides insight into the regulation
of the human p21
(waf1/cip1) gene by 1a,25(OH)2D3. Further we
demonstrate that whole promoter ChIP screening with anti-
VDR and anti-p53 antibodies is suitable for RE identiﬁcation
and that within 7.1 kb of the p21
(waf1/cip1) promoter there are
ﬁve VDREs and ﬁve p53-REs, being located, often in clusters,
at positions  1400,  2300,  4500 and  6900. This may help
to understand the physiological function of these pathways in
the process of normal mammary gland renewal and anti-
proliferative effects of 1a,25(OH)2D3 in p53 in cancer cells.
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